Clinical trial · Observational
SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access
NCT02507947CI-TRIAL-00033664withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study closed
Summary
Brief summary (as posted)
SPECTAmel is a standardized, quality-assured molecular screening platform for tumor characterization and storage of human biological material (HBM) for the purpose of integrating new biomarkers into clinical trials and optimizing access of patients to therapeutic biomarker-driven clinical trials. HBM and clinical/pathological data are collected from consenting patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Number of screened patients
- timeFrame
- 5 years
- measure
- Number of downstream clinical trials;
- timeFrame
- 5 years
- measure
- Number of patients enrolled in the downstream therapeutic trials
- timeFrame
- 5 years
- measure
- Number of exploratory/future research projects
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed melanoma of any stage (the steering committee will decide on which stage to include at any particular time point during this trial, this will be communicated appropriately to all participating sites) * Mandatory availability of adequate human biological material (HBM): FFPE tissue sample from the primary tumor, recurrent tumor, metastasis, obtained at the time of primary surgery/biopsy; minimal amount requested is detailed in the HBM guidelines; if feasible, inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional; * Age ≥ 18 years; * At least three months life-expectancy; * Written informed consent according to ICH/GCP and national/local regulations; * Absence of any active malignancy, except pT1-2 prostatic cancer Gleason score \< 6, or carcinoma in situ of the cervix, in the 5 years before study entry; * Absence of exclusion criteria like active hepatitis B/C or HIV, second malignancies, no severe organ dysfunction or other comorbidities that may prevent inclusion into clinical trials. * Central confirmation of human biological material (HBM) adequacy for step 2: * Centrally performed confirmation of tumor tissue adequacy in terms of quality/ quantity for central screening. Exclusion Criteria: * active hepatitis B/C or HIV * second malignancies * severe organ dysfunction or other comorbidities
References
Publications (0)
Data not yet available
No reference posted for this study.